Core Insights - VIO Med Spa has been selected as a key franchise partner for Obagi Medical's Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program due to its commitment to clinical excellence and innovative aesthetic care [1][4] - The partnership aims to leverage VIO Med Spa's strengths in injectables and patient education to generate real-world evidence on the performance of Obagi® saypha® MagIQ™ filler [2][3] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, known for addressing various skin concerns and recognized as the fastest-growing professional skincare brand in the U.S. in 2024 [6][10] - VIO Med Spa is a nationally recognized franchise specializing in advanced aesthetic and wellness treatments, focusing on clinical excellence and patient safety across its numerous locations [7] Program Details - The ALOHA Program will conduct a structured, multi-site assessment of the filler, emphasizing both clinical performance and patient experience while providing comprehensive protocols to enhance satisfaction and outcomes [3][4] - The program will kick off with a two-day immersive training for the VIO network, aimed at standardizing data collection across participating locations [3]

Core Insights - Obagi Medical has launched the ALOHA Program aimed at driving innovation in aesthetic practices through real-world evidence and insights [1][2] - The program will support the introduction of Obagi saypha MagIQ™, the first FDA-approved injectable hyaluronic acid filler from the company, featuring high usable HA content and a predictable injection profile [1][2] Company Overview - Obagi Medical is recognized as a leading innovator in physician-dispensed skincare with over 35 years of experience, initially known for its Obagi Nu-Derm System targeting hyperpigmentation [3] - The company is the fastest-growing professional skincare brand in the U.S. as of 2024, focusing on various skin concerns including aging, photodamage, and acne [3] Program Details - The ALOHA Program will gather real-world data from diverse practice settings to demonstrate the effectiveness of Obagi saypha MagIQ™ and its skincare products in enhancing practice success and patient satisfaction [2] - Participants in the program will provide structured feedback through standardized surveys, creating a comprehensive evaluation of the new HA injectable beyond traditional clinical trials [2] Industry Context - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands, ensuring agility and market responsiveness [4] - The company's strategy includes leveraging operational scale and expertise in managing beauty brands to mitigate category fluctuations and enhance brand performance [4]

Core Insights - Waldencast plc has acquired Novaestiq Corp, enhancing Obagi Medical's product portfolio with scientifically backed injectable products, positioning it as a leader in the health, beauty, and aesthetics convergence [1][2][6] - The acquisition allows Obagi Medical to expand into the U.S. dermal filler market, projected to reach $2 billion by 2029, effectively doubling its addressable market [1][2] - The Saypha line of hyaluronic acid injectable gels is currently undergoing FDA approval and is recognized for its safety and efficacy, supported by a robust clinical program [3][4] Company Strategy - Obagi Medical aims to integrate medical-grade skincare with aesthetic treatments, enhancing patient satisfaction and outcomes through a holistic, science-driven approach [2][5] - The company is focused on becoming the 1 Dermatological Mega Brand, leveraging a strategy that includes dermatological science, breakthrough innovations, and global expansion [5][6] - The acquisition is expected to create new growth opportunities and strengthen Obagi Medical's market position in the fast-evolving beauty and wellness industry [6] Product Details - Saypha products utilize proprietary technology for advanced HA treatments, ensuring natural-looking results and optimal gel characteristics [4] - The portfolio is backed by extensive clinical studies, emphasizing effectiveness across diverse skin types and tones [3][4] - The acquisition provides access to a future pipeline of novel injectables in North America, further diversifying Obagi Medical's offerings [2][3] Transaction Overview - The acquisition involves cash payments, ongoing royalties based on net sales of Saypha products, and contingent issuance of Waldencast class A shares based on FDA approval and revenue milestones [7] - The transaction reflects Waldencast's commitment to building a multi-brand beauty and wellness platform, enhancing operational scale and market responsiveness [8]